Anteris Technologies Reports Lapse of Restricted Stock Units and Options
I'm LongbridgeAI, I can summarize articles.Anteris Technologies Global Corp. has announced the lapse of 5,950 restricted stock units and 166 options due to unmet performance conditions, reducing potential future share issuance and slight dilution for shareholders. The latest analyst rating for Anteris Technologies (AU:AVR) is a Buy with a price target of A$10.00. The company focuses on advanced cardiovascular solutions, including transcatheter heart valve technologies.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Anteris Technologies ( (AU:AVR) ) just unveiled an announcement.
Anteris Technologies Global Corp. has announced the cessation of several equity-linked instruments, including a total of 5,950 restricted stock units and 166 options, after the relevant performance or vesting conditions were not met or became incapable of being satisfied in January 2026. The lapse of these instruments modestly reduces the company’s potential future share issuance and may slightly lessen prospective dilution for existing shareholders, while also reflecting that certain milestones tied to these securities were not achieved within the designated time frame.
The most recent analyst rating on (AU:AVR) stock is a Buy with a A$10.00 price target. To see the full list of analyst forecasts on Anteris Technologies stock, see the AU:AVR Stock Forecast page.
More about Anteris Technologies
Anteris Technologies Global Corp., listed on the ASX under the code AVR, operates in the medical technology sector, focusing on advanced cardiovascular solutions including transcatheter heart valve technologies aimed at improving structural heart disease treatment outcomes.
Average Trading Volume: 26,181
Technical Sentiment Signal: Sell